$IMAX

PABLO CALAMERA sold $786K of IMAX

PABLO CALAMERA (CTO & EVP) sold 15,000 shares of IMAX CORP (IMAX) at $52.41 ($0.79M total) on 2026-08-20.

Original reporting
SEC EDGAR · PABLO CALAMERA
Published Aug 21, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 21, 2026, 8:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$IMAX
Neutral
high confidence
Mentioned
$IMAX
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IMAXNeutralLow
01

Why it matters

The sale is routine and unlikely to move the stock significantly.

02

Market read

Small insider sale with limited trading relevance.

03

What to watch

Potential upcoming product launches or financing needs not disclosed.

Relevance 5/10Novelty 4/10Timing: post‑market 2026‑08‑20

Background

Form 4 filing discloses insider transactions; such filings are primary sources for insider activity.

Company-level read

Ticker impact

$IMAXNeutralHigh confidence
Context

CTO Pablo Calamera sold 15,000 IMAX shares for $52.41 each, reducing his stake to 43,012 shares.

Expected impact

Limited short-term impact; price likely unchanged.

Evidence & confidence

Sale size <$1M and no accompanying news suggests no material effect.

Market effects

None; IMAX operates in entertainment technology with no sector‑wide impact.

No regional effect; transaction is company‑specific.

Minimal; isolated insider sale.

Counterpoint

If the insider expects a near‑term decline, the sale could hint at downside risk.

Key entities

  • Pablo Calamera

    CTO & EVP of IMAX Corp.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$IMAXHigh

Imax is a must for movie theaters, making the stock a buy, Morgan Stanley says

Morgan Stanley initiated coverage of Imax with an overweight rating and a $63 price target, suggesting 18% upside. The bank cites Imax's growing network, film slate, and box office revenue growth. Imax's box office is projected to reach $1.7 billion in 2028, up from $1.5 billion in 2026. The success of 'The Odyssey' highlights the value of Imax's technology and brand. 12 of 14 analysts rate Imax a buy or strong buy, and shares are up 21% over the past three months.

$AMCHighAI 8/10

AMC Spikes 7% as Refinancing Pushes Maturities From 2029 to 2031; Cinemark and IMAX Edge Higher

AMC Entertainment (AMC) shares rose 7% to $2.88 after announcing debt refinancing, pushing its nearest large maturity from 2029 to 2031. The move involves a private placement of first lien notes due 2031 and a cash tender offer for outstanding 2029 notes, funded by new debt facilities. Cinemark (CNK) and IMAX (IMAX) stocks also rose, but less significantly. AMC's refinancing aims to simplify its debt structure and extend maturities, though it does not reduce the total debt.

$IMAXMed

IMAX at Bank of America 2026 Media,Communications & Entertainment Conference: global surge

IMAX Corporation (IMAX) reported strong global growth at the Bank of America 2026 Media, Communications & Entertainment Conference. CEO Rich Gelfond highlighted record box office performance, international expansion, and new revenue streams. Current-quarter box office is on track to exceed $600 million, with significant contributions from international markets and local-language films. The company operates 1,800 theaters, with 500 in backlog, and aims to expand further. IMAX is also diversifying

$IMAXMed

Why IMAX Stock Climbed to a New All-Time High Today

IMAX stock reached a new all-time high on Monday, rising 3.89% to $54.79. The surge was driven by the record-breaking success of The Odyssey, which became the highest-grossing IMAX release. CEO Rich Gelfond expects this to be their best year. Analyst Steve Frankel predicts IMAX will exceed estimates in the second half of 2026, with shares potentially rising to $60. The company's Q2 2026 revenue grew 12% to $103 million, with adjusted earnings up 65% to $0.43 per share.

$IMAXMed

“The Odyssey” Demand Drives IMAX Shares Higher

IMAX reported Q2 2026 revenue of $103M (up 12% YoY) and EPS of $0.43 (up 65%), driven by strong demand for 'The Odyssey'. The stock has gained 42% YTD, with institutional inflows contributing to a 103.5% rise over the past year. IMAX shows strong sales and EPS growth rates of 11.7% and 18.7% respectively over three years, with EPS expected to rise 14% this year.